A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

BACKGROUND: Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a novel oxazolidinone developed by LegoChem Bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dierig, A, Hoelscher, M, Schultz, S, Hoffmann, L, Jarchow-MacDonald, A, Svensson, EM, Te Brake, L, Aarnoutse, R, Boeree, M, McHugh, TD, Wildner, LM, Gong, X, Phillips, PPJ, Minja, LT, Ntinginya, N, Mpagama, S, Liyoyo, A, Wallis, RS, Sebe, M, Mhimbira, FA, Mbeya, B, Rassool, M, Geiter, L, Cho, YL, Heinrich, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243693/
https://www.ncbi.nlm.nih.gov/pubmed/37280643
http://dx.doi.org/10.1186/s13063-023-07354-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243693/
https://www.ncbi.nlm.nih.gov/pubmed/37280643
http://dx.doi.org/10.1186/s13063-023-07354-5

Ejemplares similares